After our article was published online, it was brought to our attention that in Table [1](#T1){ref-type="table"} we incorrectly stated the findings from a study testing the safety of Isradipine (Simuni et al., [@B1]). We have thus changed the text in the table to reflect the results that Isradipine has been shown to be safe and well-tolerated in PD patients.

###### 

**Neuroprotective Agents in PD models**.

  **Neuroprotective agents**                                             **Cell culture and animal studies**                                                                                                        **Human and epidemiological studies**                                                                                                                                                                                                                                                                                                                                                                                                        
  ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Caffeine                                                               A (Van den Pol, 1986; Kachroo et al., 2010)                                                                                                Decreased dopaminergic neuron toxicity in MPTP                                                                                                                                                                                                                                E (Ross et al., 2000; Ascherio et al., 2001)^\*^, Saaksjarvi et al., 2008; Costa et al., 2010)^\*^                                                             Caffeinated beverages decreased the risk of PD
  A (Chen et al., 2001; Joghataie et al., 2004; Aguiar et al., 2006)     Decreased DA loss and restored DA levels in MPTP and 6-OHDA                                                                                E (Xu et al., 2006)                                                                                                                                                                                                                                                           Caffeinated beverages have no effect on PD risk                                                                                                                
  A (Joghataie et al., 2004; Aguiar et al., 2006)                        Decreased motor dysfunctions in 6-OHDA                                                                                                     H (Ascherio et al., 2003)                                                                                                                                                                                                                                                     A decrease in PD risk among women consuming caffeine and not taking hormone-replacement therapy                                                                
  A (Xu et al., 2002, 2010)                                              Caffeine increased metabolites associated with prevention of DA loss                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  A (Xu et al., 2006)                                                    Estrogen and Caffeine prevented neuroprotection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Caffeine + nicotine                                                    A (Trinh et al., 2010)                                                                                                                     Decaffeinated coffee and nicotine-free tobacco were neuroprotective in *Drosophila*                                                                                                                                                                                           E (Tan et al., 2003)                                                                                                                                           Caffeine and nicotine combined reduced the rate of PD
  Nicotine                                                               A (Ferger et al., 1998; Costa et al., 2001)                                                                                                Nicotine reduced DA depletion resulting from MPTP and 6-OHDA                                                                                                                                                                                                                  E (Quick, 2004; Simon et al., 2009)                                                                                                                            Nicotine lowered the risk of developing PD
  A (Meshul et al., 2002)                                                Nicotine minimized parkinsonian contralateral rotations in 6-OHDA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  A (Quik et al., 2006)                                                  Non-human primates maintained dopaminergic function and cell loss in the SNpc was prevented with nicotine administartion                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  A (Carr and Rowell, 1990)^\*^                                          Tobacco smoke prior to MPTP treatment reduced the loss of striatal DA in mice                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Urate and UA                                                           A/C (Jones et al., 2000; Duan et al., 2002)                                                                                                UA protects against DA-induced apoptosis                                                                                                                                                                                                                                      E (de Lau et al., 2005, Annanmaki et al., 2007, Chen et al., 2009), Alonso et al., 2007)^\*^, (Schwarzschild et al., 2008)^\*^, (Andreadou et al., 2009)^\*^   Decreased risk of PD with UA and urate
                                                                                                                                                                                                                    H (Ascherio et al., 2009)                                                                                                                                                                                                                                                     Slower rates of clinical progression of PD were seen with UA intake                                                                                            
                                                                                                                                                                                                                    H (de Lau et al., 2005; Schwarzschild et al., 2008)                                                                                                                                                                                                                           Serum UA correlates with a decreased risk of PD                                                                                                                
  Vitamin E                                                              A (Odunze et al., 1990)                                                                                                                    Vitamin E deficiency increases MPTP toxicity                                                                                                                                                                                                                                  E (Zhang et al., 2002; Etminan et al., 2005)^\*^                                                                                                               Protection from PD with moderate vitamin E intake
  A (Lan and Jiang, 1997; Roghani and Behzadi, 2001)                     Vitamin E supplimentation protected DA neurons in the SNpc and reduced DA loss                                                             H (Fernandez-Calle et al., 1992; LeWitt, 1994; Morens et al., 1996)                                                                                                                                                                                                           Clinical trials also show no neuroprotective benefit of taking vitamin E                                                                                       
  A (Gong et al., 1991; Chi et al., 1992)                                Striatal DA was not attenuated by pretreatment of vitamin E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  C (Offen et al., 1996)                                                 Vitamin E has no protective effects against DA-induced toxicity in PC12 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  A (Perry et al., 1987)                                                 Vitamin E partially protected DA neurons in MPTP rodents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Vitamin E + vitamin C                                                                                                                                                                                                                                                                                                                                                                                                                                                                           H (Fahn, 1992)                                                                                                                                                 Both vitamins combined decreased PD progression in early stage patients
  Vitamin C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       H (Scheider et al., 1997; Zhang et al., 2002; Etminan et al., 2005)                                                                                            Few beneficial effects are seen with vitamin C and even an increased risk of PD
                                                                                                                                                                                                                    H (Perlmutter, 1988)                                                                                                                                                                                                                                                          Vitamin C intake reduced the risk of PD by 40%                                                                                                                 
  Vitamin D                                                              C (Butler et al., 2011)                                                                                                                    Disruption of Vitamin D\'s Ca^2+^ homeostasis properties accelerated SNpc dopaminergic neuron loss                                                                                                                                                                            E (Anderson et al., 1999)                                                                                                                                      An increased risk of PD is associated with high consumption of vitamin D
  H/A (Gash et al., 1996; Kordower et al., 2000), (Gill et al., 2003)    GDNF stimulation by Vitamin D can alleviated PD symptoms in primates and PD patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  C/A (Wang et al., 2001; Smith et al., 2006)                            Vitamin D produced beneficial effects against PD characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  A (Holick, 2007)                                                       Vitamin D increased neuromuscular function in parkinsonian rodents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Beta-carotene                                                          (Perry et al., 1985, 1987; Yong et al., 1986)                                                                                              Beta-carotene protected against MPTP neurotoxicity in mice, but not primates                                                                                                                                                                                                  E (Perlmutter, 1988)                                                                                                                                           A decrease in the risk of PD was seen with high B-carotene intake
  Riboflavin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      E (Perlmutter, 1988; Murakami et al., 2010)                                                                                                                    Reduced risk of PD, with high raboflavin intake by 51%
                                                                                                                                                                                                                    E (Coimbra and Junqueira, 2003)                                                                                                                                                                                                                                               Riboflavin supplimentation improved motor capacity of PD patients                                                                                              
  CoQ10                                                                  A (Shults et al., 1999)                                                                                                                    CoQ10 protected nigrostriatal dopaminergic neurons in MPTP                                                                                                                                                                                                                    H (Shults et al., 2002; Shults, 2003; Galpern and Cudkowicz, 2007)                                                                                             Chronic administration of CoQ10 delayed progression of PD in patients with no adverse affects in Phase II
  A (Cleren et al., 2008)                                                CoQ10 supplementation diminished neural tissue damage and prevented DA depletion in SNpc                                                   Investigators (2007)                                                                                                                                                                                                                                                          Inconclusive results of CoQ10 supplement showing neuroprotection in PD patients                                                                                
  CoQ10 + vitamin E                                                                                                                                                                                                                                                                                                                                                                                                                                                                               H (Shults et al., 2004)                                                                                                                                        Combination showed beneficial for PD patients, however, Phase III trials deemed it futile (NINDS, see text footnote 1)
  Creatine                                                               A (Matthews et al., 1999)                                                                                                                  Creatine protected against MPTP-induced DA depletion in the SNpc                                                                                                                                                                                                              Investigators (2006)                                                                                                                                           Creatine delayed the progression of PD by 50%
                                                                                                                                                                                                                    Investigators (2008)                                                                                                                                                                                                                                                          Creatine showed efficacy as a neuroprotective agent in PD and is currently in Phase III trials (NET-PDLS, see text footnote 2)                                 
  CoQ10 + creatine                                                       A/H (Yang et al., 2009)                                                                                                                    Combination showed a neuroprotective effect in chronic MPTP and humans                                                                                                                                                                                                                                                                                                                                                                       
  DHA                                                                    A (Bousquet et al., 2008)                                                                                                                  DHA supplements replaced omega-6 fatty acids after MPTP                                                                                                                                                                                                                                                                                                                                                                                      
  C (Wang et al., 2003)                                                  Neurons were protected against cytotoxicity with DHA intake                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  A (Ozsoy et al., 2011)                                                 DHA decreased apoptosis of dopaminergic cells in MPTP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  A (Samadi et al., 2006)                                                DHA reduced 40% of the levodopa-induced dyskinesias in Parkinsonian primates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  A (Bousquet et al., 2008)                                              DHA preserved DA levels from MPTP-induced neurotoxicity in mice                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  DHA + uridine                                                          A (Wurtman et al., 2006; Sakamoto et al., 2007)                                                                                            This combination increased levels of neural phosphatides, proteins in synaptic membranes, and dendritic spines in rodents                                                                                                                                                                                                                                                                                                                    
  A (Cansev et al., 2008)                                                DHA and uridine administration also reduced parkinsonian related behaviors and elevated DA levels in 6-OHDA rats                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Melatonin                                                              A (Acuna-Castroviejo et al., 1997; Kim et al., 1998; Maharaj et al., 2006a)                                                                Neuronal cell death damage induced by MPTP, 6-OHDA, and iron was protected with Melatonin administration                                                                                                                                                                      H (Dowling et al., 2005)                                                                                                                                       Melatonin improved duration of sleep and reduced sleep disturbances in PD patients
  A (Mayo et al., 1998, 1999)                                            Melatonin blocked apoptosis and necrosis in 6-OHDA and PC12 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  A (Tapias et al., 2010)                                                Striatal DA depletion and DA neuron loss increased after melatonin treatment of rotenone-induced Parkinsonism                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  GSH                                                                    A (Garrido et al., 2011)                                                                                                                   Excessive or reduced GSH levels initiated degeneration of DA neurons                                                                                                                                                                                                                                                                                                                                                                         
  C (Schulz et al., 2000)                                                Decreased GSH increased neuron susceptibility to neurotoxins, but did not correlate to DA viability or striatal terminals                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  A (Klivenyi et al., 2000)                                              Depletion of DA was seen after MPTP treatment in GSH peroxidase-deficient mice                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  A (Pileblad et al., 1989; Seaton et al., 1996; Wullner et al., 1996)   Low levels of GSH reduced DA neurons after toxin administration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  IP6                                                                    A/C (Xu et al., 2008, 2011)                                                                                                                IP6 inhibited MPTP, 6-OHDA, and iron toxicity in cell culture                                                                                                                                                                                                                                                                                                                                                                                
  A (Xu et al., 2008)                                                    IP6 increased cell survival in MPTP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  A (Obata, 2003)                                                        IP6 suppressed hydroxyl radical formation after MPP+ treatment in rats                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  NSAID (ibuprofen+ aspirin)                                             A/C (Bilodeau et al., 1995; Kaufmann et al., 1997; Aubin et al., 1998; Saini et al., 1998; Casper et al., 2000; Sairam et al., 2003)       NSAID\'s protected against neuronal death and dopaminergic neurotoxicity                                                                                                                                                                                                      E (Chen et al., 2003; Ton et al., 2006; Wahner et al., 2007; Gao et al., 2011)                                                                                 NSAID\'s lowered the risk of PD
                                                                                                                                                                                                                    E (Chen et al., 2005; Ton et al., 2006; Driver et al. 2011, Gao et al., 2011)                                                                                                                                                                                                 A reduction in PD risk was observed with Ibuprofen, but not NSAIDS or Acetaminophen                                                                            
  A/C (Esposito et al., 2007)                                            NSAIDS showed neuroprotection in MPTP, 6-OHDA, and *in vitro*                                                                              E (Becker et al., 2011)                                                                                                                                                                                                                                                       NSAID\'s and aspirin showed no association with altering the risk of PD                                                                                        
  A (Casper et al., 2000, Morioka et al., 2004, Carrasco et al., 2005)   Ibuprofen protected DA neurons against glutamate toxicity and decreased MPTP toxicity                                                      E (Bower et al., 2006; Hernan et al., 2006)                                                                                                                                                                                                                                   Increased risk of PD shown with moderate aspirin intake                                                                                                        
                                                                                                                                                                                                                    E (Samii et al., 2009, Seroka, 2010)                                                                                                                                                                                                                                          Ibuprofen reduced the risk of developing PD in humans by 40%                                                                                                   
  Isradipine                                                             A (Ilijic et al., 2011)                                                                                                                    Isradipine showed neuroprotection against 6-OHDA                                                                                                                                                                                                                              H (Simuni et al., 2010)                                                                                                                                        Isradipine has been shown to be safe and well-tolerated in PD patients
  Phenylbutyrate                                                         C (Gardian et al., 2004; Zhou et al., 2011)                                                                                                Phenylbutyrate protected DA neurons in the SNpc                                                                                                                                                                                                                                                                                                                                                                                              
  A (Zhou et al., 2011)                                                  Reduced deterioration in motor and cognitive function in mice                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Ex-4                                                                   A (Li et al., 2009)                                                                                                                        Protected DA neuron degeneration, preserved DA levels, and improved motor function in rodents                                                                                                                                                                                                                                                                                                                                                
  A/C (Harkavyi et al., 2008; Li et al., 2009)                           Ex-4 protected ventral mesencephalic dopaminergic cells in culture, reverse nigral lesions, and protected against 6-OHDA toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Ragasiline                                                             C (Heikkila et al., 1985; Huang et al., 1999; Speiser et al., 1999; Maruyama et al., 2000; Sagi et al., 2001; Youdim et al., 2001a)        Reduces MPTP and 6-OHDA toxicity in PC12 and SH-SY5Y cells                                                                                                                                                                                                                    H (Hauser et al., 2009; Olanow et al., 2009)                                                                                                                   Rasagiline reduced the long-term progression and symptoms in PD
  A (Kupsch et al., 2001, Sagi et al., 2001)                             Rasagiline prevented nigrostriatal damage induced by MPTP in primates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  A (Blandini et al., 2004)                                              Rasagiline increased DA neuron survival in lesioned SNpc and improved motor impairments                                                    H (Rascol et al., 2011)                                                                                                                                                                                                                                                       Rasagiline in a Phase III delayed the need for antiparkinsonian drugs and patients had lower scores on the Parkinson\'s disease rating scale                   
  C (Murer et al., 2001)                                                 Rasagiline increased expression of neurotrophins                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Minocycline                                                            A/C (Du et al., 2001)                                                                                                                      Minocycline blocked MPTP-induced degeneration of DA neurons in the SNpc\~ preventing loss of striatal DA and its metabolites. Minocycline treatment also inhibited MPP+ mediated inducible NO synthase expression *in vivo* and blocked NO-induced neurotoxicity *in vitro*   H (Investigators, 2006)                                                                                                                                        Minocycline was deemed effective in Phase II slowing the progression of PD in patients. An 18-month follow up study showed no safety concerns with its use (Investigators, 2008), leading to Phase III trials
  A (Faust et al., 2009; Radad et al., 2010)                             DA neuroprotection by Minocycline was seen in a *Drosophila* model of PD and after rotenone toxicity in rodents                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  A (Quintero et al., 2006)                                              Reduced the number of apomorphine-induced rotations in 6-OHDA-lesioned rats                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  A/C (Yang et al., 2003)                                                Minocycline exacerbated MPTP damage to DA neurons *in vitro* and *in vivo*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  A (Diguet et al., 2004)                                                Minocycline treatment in primates and mice produced more severe/rapid parkinsonism, behavior deficits, and greater loss of nerve endings                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Minocycline + creatine                                                                                                                                                                                                                                                                                                                                                                                                                                                                          H (NET-PD, 2006)                                                                                                                                               Reduced progression in PD patients in Phase II

*C, cell culture; A, animal; H, human; and E, epidemiological. Studies showing gender specificity, where males show favorable results are denoted (^\*^)*.
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